(1) A student
enrolling in kindergarten through sixth grade shall be immunized in accordance
with the Advisory Committee on Immunization Practices (ACIP) Recommendations,
as listed in Subsection
R396-100-3(4),
before school entry for the following vaccines and doses:
(a) Measles, Mumps, Rubella (MMR)- 2
doses;
(b) Varicella- 2
doses;
(c) Hepatitis B- 3
doses;
(d) Polio- 4 doses, dose
number 4 is not necessary if dose 3 was administered at age 4 years or older
and at least 6 months after the previous dose;
(e) Hepatitis A- 2 doses; and
(f) Diphtheria, Tetanus, and Pertussis
(DTaP)- 5 doses, dose 5 is not necessary if dose 4 was administered at age 4
years or older and at least 6 months after dose 3.
(2)
(a) A
student enrolling in seventh through twelfth grade:
(b) Must be immunized in accordance with the
ACIP Recommendations, as listed in Subsection
R396-100-3(4),
before school entry for the following vaccines and doses:
(i) Tetanus, Diphtheria, and acellular
Pertussis (Tdap)-One dose;
(ii)
Measles, Mumps, Rubella (MMR)- 2 doses;
(iii) Varicella- 2 doses;
(iv) Hepatitis B- 3 doses;
(v) Polio- 4 doses, dose 4 is not necessary
if dose 3 was administered at age 4 years or older and at least 6 months after
the previous dose;
(vi) Hepatitis
A- 2 doses; and
(vii) Meningococcal
Conjugate Vaccine- One dose.
(c) Must provide proof of previously
receiving five doses of DTaP vaccine or 4 doses if dose 4 was administered at
age 4 years or older and at least 6 months after dose 3. A student who has
never been vaccinated with DTaP vaccine or who was not fully vaccinated with
DTaP vaccine as provided by Subsection
R396-100-3(1)(f),
must be immunized with the appropriate number of doses of Tetanus, Diphtheria
(Td) or Tdap vaccine in accordance with the catch-up Immunization schedule for
children and adolescents who start late or who are more than one month
behind.
(4) The
vaccinations must be administered according to the recommendations of the
United States Public Health Service's Advisory Committee on Immunization
Practices (ACIP) which are incorporated by reference into this rule:
(a) General Recommendations on Immunization:
MMWR, December 1, 2006/Vol. 55/No. RR-15;
(b) General Recommendations on Immunization:
MMWR, January 28, 2011; 60(RR02):1-60;
(c) Immunization of Adolescents: MMWR,
November 22, 1996/Vol. 45/No. RR-13;
(d) Combination Vaccines for Childhood
Immunization: MMWR, May 14, 1999/Vol. 48/No. RR-5;
(e) Use of Diphtheria Toxoid-Tetanus
Toxoid-Acellular Pertussis Vaccine as a Five-Dose Series: Supplemental
Recommendations of the Advisory Committee on Immunization Practices: MMWR
November 17, 2000/Vol. 49/No. RR-13;
(f) Licensure of a Diphtheria and Tetanus
Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus influenzae
Type b Conjugate, and Hepatitis B Vaccine, and Guidance for Use in Infants:
MMWR, February 7, 2020, 69 (5);136-139;
(g) Prevention of Pertussis, Tetanus, and
Diphtheria with Vaccines in the United States: Recommendations of the Advisory
Committee on Immunization Practices (ACIP): MMWR, April 27, 2018; 67
(2):1-44;
(h) Updated
Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria Toxoid and
Acellular Pertussis (Tdap) Vaccine from the Advisory Committee on Immunization
Practices, 2010: MMWR, January 14, 2011; 60(01):13-15;
(i) Use of Tetanus Toxoid, Reduced Diphtheria
Toxoid and Acellular Pertussis Vaccines Among Adolescents: MMWR, March 24,
2006, Vol. 55(RR03):1-49;
(j) Use
of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccines:
Updated Recommendations of the Advisory Committee on Immunization Practices:
MMWR, January 24, 2020, Vol. 69 (3);77-83;
(k) A Comprehensive Immunization Strategy to
Eliminate Transmission of Hepatitis B Virus Infection in the United States.
Part 1: Immunization of Infants, Children and Adolescents: MMWR, December 23,
2005, Vol. 54(RR-16):1-39;
(l)
Prevention of Hepatitis B Virus Infection in the United States: Recommendations
of the Advisory Committee on Immunization Practices: MMWR, January 12, 2018; 67
(1); 1--31;
(m) Haemophilus b
Conjugate Vaccines for Prevention of Haemophilus influenza Type b Disease Among
Infants and Children Two Months of Age and Older: MMWR, January 11, 1991/Vol.
40/No. RR-1;
(n) Recommendations
for Use of Haemophilus b Conjugate Vaccines and a Combined Diphtheria, Tetanus,
and Pertussis, and Haemophilus b Vaccine: MMWR, September 17, 1993/Vol. 42/No.
RR-13;
(o) Prevention and Control
of Haemophilus influenzae Type b Disease: Recommendations of the Advisory
Committee on Immunization Practices (ACIP) Recommendations and Reports: MMWR,
February 28, 2014; 63(RR01):1-14;
(p) Updated Recommendations of the Advisory
Committee on Immunization Practices (ACIP) for the Control and Elimination of
Mumps: MMWR, June 9, 2006/Vol. 55/No. RR-22;
(q) Measles, Mumps, Rubella Vaccine
(PRIORIX): Recommendations of the Advisory Committee on Immunization Practices
--- United States, 2022: MMWR, November 18, 2022, 71 (46); 1465-1470;
(r) Prevention of Measles, Rubella,
Congenital Rubella Syndrome, and Mumps, 2013 -- Summary Recommendations of the
Advisory Committee on Immunization Practices (ACIP): MMWR, June 14, 2013;
62(RR04):1-34;
(s) Use of
Combination Measles, Mumps, Rubella, and Varicella Vaccine--Recommendations of
the Advisory Committee on Immunization Practices: MMWR, May 7, 2010;
59(RR--3):1 -- 16;
(t) Updated
Recommendations of the Advisory Committee on Immunization Practices (ACIP)
Regarding Routine Poliovirus Vaccination: MMWR, August 7, 2009/Vol. 58/No.
30;
(u) Poliomyelitis Prevention in
the United States: MMWR May 19, 2000 / Vol. 49 / No. RR-05;
(v) Prevention of Varicella: MMWR, June 22,
2007/Vol. 56/No. RR-4;
(w)
Prevention of Hepatitis A Through Active or Passive Immunization: MMWR, May 29,
2006/Vol. 55/No. RR-7;
(x)
Prevention of Hepatitis A Virus Infection in the United States: Recommendations
of the Advisory Committee on Immunization Practices: MMWR, July 3, 2020, Vol.
69 (5);1-38;
(y) Licensure of a
13-Valent Pneumococcal Conjugate Vaccine (PCV13) and Recommendations for Use
Among Children-Advisory Committee on Immunization Practices, (ACIP), 2010: MMWR
March 12, 2010/Vol. 59/No. 09;
(z)
Use of 15-Valent Pneumococcal Conjugate Vaccine Among U.S. Children: Updated
Recommendations of the Advisory Committee on Immunization Practices-US, 2022:
MMWR, September 16, 2022, 71(37);1174--1181;
(aa) Preventing Pneumococcal Disease Among
Infants and Young Children: MMWR October 6, 2000 /Vol. 49 / No.
RR-09;
(bb) Prevention and Control
of Meningococcal Disease: Recommendations of the Advisory Committee on
Immunization Practices (ACIP): March 22, 2013/62(RR02);1-22;
(cc) Meningococcal Vaccination:
Recommendations of the Advisory Committee on Immunization Practices: MMWR,
September 25, 2020, Volume 69(9); 1--41;
(dd) Licensure of a Meningococcal Conjugate
Vaccine (Menveo) and Guidance for Use--Advisory Committee on Immunization
Practices (ACIP), 2010: MMWR, March 12, 2010; 59(09):273; and
(ee) Updated Recommendations for Use of
Meningococcal Conjugate Vaccines--Advisory Committee on Immunization Practices
(ACIP), 2010: MMWR, January 28, 2011; 60(03):72-76.